Shanghai Kaibao Pharmaceutical CO.,Ltd
Shenzhen Stock ExchangeTotal Valuation
Shanghai Kaibao Pharmaceutical CO.,Ltd carries a market capitalization of 4.58B, placing it among publicly traded companies globally. Its enterprise value stands at 5.54B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.58B |
| Enterprise Value | 5.54B |
Share Statistics
Shanghai Kaibao Pharmaceutical CO.,Ltd currently has 1.05B shares outstanding.
| Shares Outstanding | 1.05B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Shanghai Kaibao Pharmaceutical CO.,Ltd trades at a trailing price-to-earnings ratio of 17.83. The price-to-sales ratio is 5.07, and the price-to-book ratio stands at 2.05.
| PE Ratio | 17.83 |
| PS Ratio | 5.07 |
| PB Ratio | 2.05 |
| P/TBV Ratio | 1.55 |
| P/FCF Ratio | 370.31 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Shanghai Kaibao Pharmaceutical CO.,Ltd trades at an EV/EBITDA multiple of 16.33 and an EV/FCF ratio of 322.86. The EV/Sales ratio of 4.44 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 16.33 provides insight into valuation relative to core operating earnings.
| EV / Sales | 4.44 |
| EV / EBITDA | 16.33 |
| EV / EBIT | 16.33 |
| EV / FCF | 322.86 |
Financial Position
Shanghai Kaibao Pharmaceutical CO.,Ltd maintains a current ratio of 12.62, meaning it holds 12.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.13, indicating conservative leverage, while an interest coverage ratio of 5,076.73 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 12.62 |
| Quick Ratio | 3.95 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 0.02 |
| Interest Coverage | 5,076.73 |
Financial Efficiency
Shanghai Kaibao Pharmaceutical CO.,Ltd posts a return on equity of 11.89 and a return on invested capital of 7.55.
| Return on Equity (ROE) | 11.89 |
| Return on Assets (ROA) | 8.22 |
| Return on Invested Capital (ROIC) | 7.55 |
| Return on Capital Employed (ROCE) | 11.90 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.32 |
Taxes
Over the trailing twelve months, Shanghai Kaibao Pharmaceutical CO.,Ltd has paid 54.87M in income taxes, reflecting an effective tax rate of 13.40.
| Income Tax | 54.87M |
| Effective Tax Rate | 13.40 |
Stock Price Statistics
Shanghai Kaibao Pharmaceutical CO.,Ltd's stock has declined approximately -29.69502% over the past 52 weeks. The 50-day moving average sits at 5.13, while the 200-day moving average is 5.94.
| Beta (5Y) | N/A |
| 52-Week Price Change | -29.69502% |
| 50-Day Moving Average | 5.13 |
| 200-Day Moving Average | 5.94 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Shanghai Kaibao Pharmaceutical CO.,Ltd generated 1.25B in revenue and converted that into 355.39M in net income, yielding earnings per share of 0.34. EBITDA reached 339.58M, while operating income came in at 339.58M.
| Revenue | 1.25B |
| Gross Profit | 1.01B |
| Operating Income | 339.58M |
| Pretax Income | 409.58M |
| Net Income | 355.39M |
| EBITDA | 339.58M |
| EBIT | 339.58M |
| Earnings Per Share (EPS) | 0.34 |
Balance Sheet
Shanghai Kaibao Pharmaceutical CO.,Ltd holds 799.74M in cash and equivalents against 5.58M in total debt, resulting in a net debt position of -606.81M. Total book value stands at 3.10B, with working capital of 2.35B providing operational flexibility.
| Cash & Cash Equivalents | 799.74M |
| Total Debt | 5.58M |
| Net Debt | -606.81M |
| Equity (Book Value) | 3.10B |
| Book Value Per Share | 2.96 |
| Working Capital | 2.35B |
Cash Flow
After subtracting -17.11M in capital expenditures, free cash flow totaled -17.11M - equivalent to -0.02 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -17.11M |
| Free Cash Flow | -17.11M |
| FCF Per Share | -0.02 |
Margins
Shanghai Kaibao Pharmaceutical CO.,Ltd operates with a gross margin of 81.25, reflecting its pricing power and cost economics. The operating margin of 27.19 and net profit margin of 28.46 provide insight into operational efficiency.
| Gross Margin | 81.25 |
| Operating Margin | 27.19 |
| Pretax Margin | 32.80 |
| Profit Margin | 28.46 |
| EBITDA Margin | 27.19 |
Dividends & Yields
The company's payout ratio of 29.56 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.10 |
| Dividend Yield | N/A |
| Payout Ratio | 29.56 |
| Shareholder Yield | 1.57 |
| FCF Yield | 0.27 |
Stock Splits
Shanghai Kaibao Pharmaceutical CO.,Ltd's most recent stock split took place on May 10, 2017 with a 10:13 split ratio.
| Last Split Date | 5/10/2017 |
| Split Ratio | 10:13 |
Scores
Shanghai Kaibao Pharmaceutical CO.,Ltd posts an Altman Z-Score of 11.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 11.07 |